Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre

Barugola, Giuliano; Partelli, Stefano; Crippa, Stefano; Butturini, Giovanni; Salvia, Roberto; Sartori, Nora; Bassi, Claudio; Falconi, Massimo; Pederzoli, Paolo

doi:10.1111/hpb.12073

Cited by 15 publications

(9 citation statements)

References 33 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies from the United States as well as Italy suggest that both perioperative and overall survival following surgery have improved significantly over the past 25 years [65,66]. Adjuvant chemotherapy has become a mainstay following resection of PDAC and the role of adjuvant chemoradiation remains to be clearly defined [67,68,69,70,71].…”

Section: Adjuvant Therapymentioning

confidence: 99%

Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma

Loehrer¹,

Ferrone²

2016

Dig Surg

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is increasingly common and a leading cause of cancer-related mortality. Surgery remains the only possibility for cure. Upwards of 40% of patients present with locally advanced PDAC (LA-PDAC), where management strategies continue to evolve. In this review, we highlight current trends in neoadjuvant chemotherapy, surgical resection, and other multimodality approaches for patients with LA-PDAC. Despite promising early results, additional work is needed to more accurately and appropriately tailor treatment for patients with LA-PDAC.

show abstract

Section: Adjuvant Therapymentioning

confidence: 99%

Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma

Loehrer¹,

Ferrone²

2016

Dig Surg

View full text Add to dashboard Cite

show abstract

“…2 Following surgery, most patients experience recurrence and succumb to their disease. 3,4 Despite progress in surgical and perioperative management, as well as adjuvant treatment with chemotherapy and/ or radiation therapy, long-term survival following pancreatectomy for cancer is still poor, with recent series reporting median disease-specific survival of 29 months, 5 median overall survival (OS) of 27 months, 6 and 5-year OS rates of 23%. 7 Furthermore, these values represent actuarial survival estimated using Kaplan-Meier methods; actual 5-year survival following PC resection has been reported to be between 12 and 18%.…”

Section: Introductionmentioning

confidence: 99%

The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection

Kagedan

Raju

Dixon

et al. 2016

HPB

View full text Add to dashboard Cite

show abstract

“…1C) has improved during the time period of 2009-2013. This bene t may result from the improvements of high-quality imaging techniques [19] and the multidisciplinary team management of pancreatic cancer [22]. Unfortunately, we did not observe the survival bene t in elderly patients.…”

mentioning

confidence: 69%

A Time-Trend Survival Analysis of Elderly Resectable Pancreatic Cancer Patients

Jiang

Shang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The time-trend in the survival of elderly pancreatic cancer patients was still unclear. Thus, the aim of this study was to compare the survival benefit of young and elderly pancreatic cancer patients by a time-trend analysis. Methods: From 2004-2013, we obtained 5,341 of young patients (< 80 years) and 569 elderly patients (≥ 80 years) from the Surveillance, Epidemiology, and End Results (SEER) database, and the overall survival of these patients were analyzed by Kaplan-Meier estimator. The independent factors which could predict the survival of patients were determined by cox proportional hazards model.Results: We observed that the median overall survival of the young patients in 2004-2008 cohort was significantly (P < 0.001) increased when compared to that in the 2009-2013 cohort. However, we did not observe the survival benefit for the elderly patients. The Cox proportional hazards model demonstrated that the tumor size, lymph node ratio, grade, and AJCC TNM stage were independent factors of survival. Conclusions: This study demonstrated that compared to 2004-2008, the survival of elderly patients in 2009-2013 was not significantly improved. Thus, the clinicians still need to administer more care to elderly patients.

show abstract

Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre

Abstract: Longterm survival after surgery for pancreatic cancer significantly improved over the period under study. Better patient selection and the routine use of adjuvant therapy may account for this improvement.

Cited by 15 publications

References 33 publications

Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma

Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma

The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection

A Time-Trend Survival Analysis of Elderly Resectable Pancreatic Cancer Patients

Contact Info

Product

Resources

About